SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

CSPC Anbenitamab Cuts Death Risk 61% in Phase III Gastric Cancer Trial

Anbenitamab reduced the risk of death by 61% in a Phase III trial in advanced HER2-positive gastric cancer.

Related stories